Biotech | April 11, 2022
Lonza signs manufacturing deal with Asher Biotherapeutics
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Dr. Kalyan Banerjee's Clinic developed a homeopathy prophylaxis protocol for the prevention of Covid-19 as soon as the pandemic began
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
With this move, government hospitals across India can now access the geko device to prevent life-threatening blood clots, and address complications related to swelling following orthopaedic surgery and the healing of chronic wounds (leg ulcers)
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Subscribe To Our Newsletter & Stay Updated
